BzODZ-EPyr.

BzODZ-EPyr belongs to the line of cannabimimetic aminoalkylindoles, with one structural peculiarity: the ketone bridge that links the indole core to the aromatic group in JWH-type compounds is here replaced by a 1,2,4-oxadiazole ring bearing a benzyl group, while the indole nitrogen carries a 2-(pyrrolidin-1-yl)ethyl chain. This is what the series it comes from sets out to establish: swapping the spacer in this way generally retains activity at the CB1 receptor. The founding patent designates it as a particularly preferred compound; in its Table 1, the compound binds to CB1 with an IC50 of 0.05 µM (rat cerebellum) and to CB2 with an IC50 of 1.6 µM (rat spleen), and inhibits the contraction of the mouse vas deferens by 80% at 1.0 µM. Beyond that point the file is thin: no measurement of affinity or efficacy in a recombinant human system, hence no quantification of the agonism, no functional effect measured at CB2, nothing on the neighbouring targets TRPV1, GPR55, PPARγ and 5-HT1A, no pharmacokinetic, metabolic or toxicological study specific to this compound, and human data are entirely lacking. That void is itself a major limitation: nothing allows the observations made on other synthetic agonists, including its analogues, which often differ by a single atom, to be transposed to this molecule.

Source

An entirely synthetic molecule. It occurs neither in cannabis nor in any other plant or living organism, and bears no relation to hemp or to cannabidiol products. The only identification found outside the laboratory, on the illicit market for new psychoactive substances, comes from a team in Ekaterinburg (Russia) and was published online in December 2015 (Shevyrin et al., 2016).

No biosynthetic pathway exists: the molecule is produced by no living organism and comes from organic synthesis.

European Union

No Union instrument covering this molecule has been found, and no notification to the Union's Early Warning System could be found: the published identification comes from Russian teams, outside the Union. At international level, it appears in no schedule of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025). Several countries nevertheless apply generic laws by chemical family, or blanket laws on new psychoactive substances, which may cover it without naming it, such as point 2.1.2 of the annex to the German law on new psychoactive substances (NpSG), which admits as a bridge nitrogen heterocycles of up to five atoms: its status must therefore be checked country by country, and it changes quickly for this type of compound.

France

Not classified as a narcotic in France. The molecule appears neither under its abbreviation nor under its systematic name in the consolidated list of substances classified as narcotics maintained by the ANSM, in which the oxadiazole motif is entirely absent. Nor does it fall within the generic definitions of annex IV of the decree of 22 February 1990, and this for two independent reasons. First, these generic families are defined by their bridge or core, notably: indol-3-yl methanone, indazol-3-yl methanone, indole or indazole 3-carboxylate and 3-carboxamide, pyrrolo[3,2-c]pyridine carboxamide, 3-(4-thiazolyl)indole derivatives; none covers a 1,2,4-oxadiazole bridge. Second, the exhaustive list of substituents permitted on the indole nitrogen, of the alkyl, haloalkyl, halobenzyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, methyl-oxane, 1-(N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl type, does not include the 2-(pyrrolidin-1-yl)ethyl chain carried by this molecule. The generic clause covering tetrahydrocannabinols, their esters, ethers and salts (in annex III of the consolidated list since the decision of 6 February 2026) does not apply either, for want of any structural kinship with THC. This absence of classification describes a state of the law and not an absence of risk: the ANSM regularly extends the list, as it has done for other synthetic cannabinoids.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

1-aminoalkylindole with a 1,2,4-oxadiazole bridge (3-benzyl-oxadiazol-5-yl)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

BzODZ-EPyr (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Moloney GP, Angus JA, Robertson AD et al., Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008;43(3):513-539 (new tab)PMID 17582659
2. 2Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y, Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances. Forensic Sci Int. 2016;259:95-100 (new tab)PMID 26771874
3. 3Moloney PG, Robertson AD, patent US 6930118 B2, 3-Oxadiazol-5-yl-1-aminoalkyl-1H-indole derivatives, Amrad Operations Pty Ltd, priority of 2 November 2000, filed 2 November 2001, granted 16 August 2005; table 1, compound 1: binding IC50 CB1 0.05 µM and CB2 1.6 µM, 80% inhibition of mouse vas deferens contraction at 1.0 µM (new tab)
4. 4ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (Annex IV: generic families of indoles, indazoles, pyrroles; no oxadiazole entry; Annex III: tetrahydrocannabinols clause) (new tab)
5. 5INCB, Green List of psychotropic substances, 36th edition, 2025 (1971 Convention: BzODZ-EPyr absent) (new tab)
6. 6Annex to the German law on new psychoactive substances (NpSG), point 2.1 (cannabimimetics), 2.1.2 d: nitrogen heterocycles of at most five atoms as a bridge (new tab)
7. 7PubChem CID 9842447: BzODZ-EPyr (identifiers, average mass 372.5; CAS 422564-85-0) (new tab)

SMILES

c1ccc(Cc2noc(-c3cn(CCN4CCCC4)c4ccccc34)n2)cc1

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.